Tokyo, April 20 (Jiji Press)–Life Science Institute Inc. of Japan said Tuesday that it will launch in May a clinical trial for regenerative treatment for severely ill novel coronavirus patients using multilineage-differentiating stress-enduring, or Muse, cells.
The therapy is expected to help repair lungs and other organs damaged by the virus and lower the death rate among coronavirus patients, according to the Mitsubishi Chemical Holdings Corp. <4188> subsidiary.
The clinical trial will be carried out at medical facilities, including Nagoya University Hospital in Aichi Prefecture, central Japan.
Preparations made from Muse cells will be intravenously administered to 43 patients on artificial ventilators due to acute respiratory failure, a serious symptom related to the virus.
The company aims to confirm the safety and efficacy of the treatment through the trial.
Muse cells are naturally found in bone marrow and other parts of human bodies. They usually accumulate in injured organs to repair damage. They are also thought to be capable of mitigating symptoms caused by immune system overreaction, such as severe inflammation, as well as sequelae.